Danish UVISA opens waiting list for light-based device targeting vaginal infections
Planned US market debut in 2026
UVISA, a Copenhagen-based medtech company developing a light-therapy device for common vaginal infections, has opened a waiting list ahead of its planned market debut in 2026.
The reusable, at-home device is being designed to address symptoms of bacterial vaginosis (BV) and yeast infections — two conditions that affect large numbers of women but are often difficult to treat, particularly when standard antibiotics or antifungals fail.
The company says the technology offers a drug-free alternative for those experiencing recurring discomfort or irritation. Human testing is currently underway in Odense.
“Currently we’re validating its safety and effectiveness through human trials in Odense, and the amount of interested women has been overwhelming,” said Sonal Pendharkar Kulkarni, CSO and co-founder of UVISA Health. “
We’re seeing great progress, and while I cannot share details yet, I’m proud to say that we’re getting closer to the launch of our solution.”
UVISA expects to bring the device to the US market in 2026, followed by the EU in 2027 or 2028. The waiting list is aimed at early adopters who want to access the product once regulatory steps are completed.
Ella Harris, CEO and co-founder, said the opening of the list reflects the company’s confidence in its progress.
“As others in the industry know, developing a medical device is never a quick journey. It takes time, evidence, and care to ensure safety and real clinical value, and we’re proud to show progress. Opening the waiting list is a testament to our confidence in the diligent process we have been following.”
Harris added that the company’s mission is centred on those who struggle with recurrent infections.
“Our vision is clear: we want to help millions of women to finally feel better equipped when a vaginal infection strikes. We’re talking about women who tried all solutions and still feel lost. We’re here for them, offering them understanding and relief.”
UVISA has not yet released further details on device performance or regulatory milestones. The company says these will follow as trials progress.